Genmab risk profile
44 Elevated one input has moved against it
Measured 21 October 2026 from GMAB.CO's filed statements. Recomputed nightly.
44 (Elevated), driven by Concentration at 87, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 25 | Normal | Stable | One-year price volatility — 34.7% |
| Operating pressure | 68 | Stretched | Worsening | Costs outgrowing revenue — +7.0 percentage points |
| Cash conversion | 22 | Normal | Easing | Cash conversion — 1.23x |
| Leverage and coverage | Reads total_debt, cash_and_cash_equivalents, ebitda, interest_expense, total_current_assets, total_current_liabilities and a disclosed CET1 ratio, for a bank or insurer. No reading is stored for this company. | |||
| Competitive position | 12 | Contained | Stable | Operating-margin gap against peers — +16.8 percentage points |
| Concentration | 87 | Acute | Stable | Geographic concentration — 8,050 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.